Compare TKLF & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | CANF |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | Japan | Israel |
| Employees | 160 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 6.7M |
| IPO Year | 2020 | 2011 |
| Metric | TKLF | CANF |
|---|---|---|
| Price | $1.58 | $1.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 11.5K | ★ 28.3K |
| Earning Date | 07-10-2026 | 09-08-2026 |
| Dividend Yield | ★ 15.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $0.17 |
| 52 Week High | $3.62 | $10.40 |
| Indicator | TKLF | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 21.36 |
| Support Level | $1.30 | N/A |
| Resistance Level | $1.63 | $2.27 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 63.64 | 0.00 |
Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.